跳至主要内容
临床试验/NCT03895034
NCT03895034已完成不适用

A Single Center Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

RxSight, Inc.1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2018年6月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
RxSight, Inc.
入组人数
66
试验地点
1
主要终点
Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better

研究概览

简要总结

The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must sign a written Informed Consent form and be willing to undergo cataract surgery for unilateral or bilateral implantation of the RxLAL.
  • Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.
  • Study eye must have cataract causing reduction in best corrected distance visual acuity (BCDVA) to a level of 20/32 or worse with or without a glare source.
  • Willing and able to comply with the requirements for study specific procedures and visits.

排除标准

  • Study eye with pseudoexfoliation.
  • Study eye with diabetes with any evidence of retinopathy.
  • Study eye with evidence of glaucomatous optic neuropathy.
  • Study eye with history of uveitis.
  • Study eye with prior history of Intacs, Radial keratotomy (RK), Conductive keratoplasty (CK), Astigmatic keratotomy (AK), Phakic Implantable Collamer Lens (ICL), Corneal Inlay, or with previous pterygium excision unless the pterygium did not extend more than 2mm onto the cornea from the limbus.
  • Subjects taking systemic medication that may increase sensitivity to UV light.
  • Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
  • Study eye with history of ocular herpes simplex virus.
  • Study eye with history of a congenital color vision defect

结局指标

主要结局

Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better

时间窗: 3 months post op

次要结局

未报告次要终点

研究者

发起方
RxSight, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验